Table 1.

Clinical trials registered on Clinicaltrials.gov that are utilising checkpoint inhibitor-based immunotherapy, and are currently recruiting or due to recruit patients with pancreatic ductal adenocarcinoma.

Trial ID	Stage of Disease	Checkpoint Inhibitor	Combined with	Phase	Number of Patients	Countries Involved
NCT03193190 [95]	IV	Atezolizumab	Cobimetinib or PEGPH20 or BL-8040	Ib–II	185	International
NCT01959672 [96]	I–III	Oregovomab	As single agent after chemotherapy and prior to Stereotactic Body Radiation Therapy	II	66	US
NCT03336216 [97]	III–IV	Nivolumab	Cabiralizumab or Cabiralizumab + chemotherapy	II	160	US
NCT03153410 [98]	II *	Pembrolizumab	Cyclophosphamide + GVAX Pancreas Vaccine + IMC-CS4	I	12	US
NCT02734160 [99]	IV	Durvalumab	Galunisertib	Ib	37	International
NCT02648282 [100]	III	Pembrolizumab	Cyclophosphamide + GVAX Pancreas Vaccine + Stereotactic Body Radiation Therapy	II	54	US
NCT03161379 [101]	II *	Nivolumab	Cyclophosphamide + GVAX Pancreas Vaccine + Stereotactic Body Radiation Therapy	II	50	US
NCT02305186 [102]	I–II *	Pembrolizumab	Radiotherapy + capecitabine	Ib–II	56	US
NCT03104439 [103]	IV	Nivolumab and Ipilimumab	Radiotherapy	II	80	US
NCT03190265 [104]	IV	Nivolumab and Ipilimumab	Cyclophosphamide + GVAX Pancreas Vaccine + CRS-207	II	63	US
NCT03006302 [105]	IV	Pembrolizumab	Cyclophosphamide + Epacadostat + CRS-207 + GVAX Pancreas Vaccine	II	70	US
NCT03098550 [106]	III–IV	Nivolumab	Daratumumab	I–II	120	International
NCT03098160 [107]	IV	Ipilimumab	Evofosfamide	I	69	US
NCT02583477 [108]	IV	Durvalumab	Nab-paclitaxel and gemcitabine or AZD5069	Ib–II	19	US, UK
NCT03168139 [109]	IV	Pembrolizumab	Olaptesed pegol	I–II	20	Germany
NCT03329248 [110]	III–IV	Avelumab	ALT-803 + ETBX-011 + GI-4000 + haNK for infusion + bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + nab-Paclitaxel + lovaza + Oxaliplatin + SBRT	I–II	80	US
NCT03080974 [111]	III	Nivolumab	Irreversible Electroporation	II	10	US

* Borderline resectable; US, United States; UK, United Kingdom.